{"id":10543,"date":"2025-01-05T12:30:00","date_gmt":"2025-01-05T04:30:00","guid":{"rendered":"https:\/\/credevo.com\/articles\/?p=10543"},"modified":"2025-07-21T18:46:27","modified_gmt":"2025-07-21T10:46:27","slug":"first-in-human-fih-clinical-trials-key-considerations-for-sponsors","status":"publish","type":"post","link":"https:\/\/credevo.com\/articles\/2025\/01\/05\/first-in-human-fih-clinical-trials-key-considerations-for-sponsors\/","title":{"rendered":"First-in-Human (FIH) Clinical Trials: Key Considerations for Sponsors"},"content":{"rendered":"\n<p>Stepping into a first-in-human (FIH) clinical trial is a defining moment in drug development. It\u2019s when a new drug that\u2019s been years in the making finally transitions from lab bench to bedside. This isn\u2019t about proving efficacy\u2014that comes later. FIH <a href=\"https:\/\/credevo.com\/articles\/2024\/02\/15\/top-8-reasons-to-choose-india-as-your-clinical-trial-destination-advantages-and-strategic-benefits\/\">clinical trials<\/a> are all about safety, tolerability, and understanding how the drug behaves in the human body.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"800\" height=\"450\" src=\"https:\/\/credevo.com\/articles\/wp-content\/uploads\/2025\/05\/First_In_Human_Clinical_Trials_Sponsors_Credevo.jpg\" alt=\"First-in-Human Trials: Key Considerations for Sponsors\" class=\"wp-image-10544\" srcset=\"https:\/\/credevo.com\/articles\/wp-content\/uploads\/2025\/05\/First_In_Human_Clinical_Trials_Sponsors_Credevo.jpg 800w, https:\/\/credevo.com\/articles\/wp-content\/uploads\/2025\/05\/First_In_Human_Clinical_Trials_Sponsors_Credevo-300x169.jpg 300w, https:\/\/credevo.com\/articles\/wp-content\/uploads\/2025\/05\/First_In_Human_Clinical_Trials_Sponsors_Credevo-768x432.jpg 768w, https:\/\/credevo.com\/articles\/wp-content\/uploads\/2025\/05\/First_In_Human_Clinical_Trials_Sponsors_Credevo-732x412.jpg 732w\" sizes=\"(max-width: 800px) 100vw, 800px\" \/><\/figure>\n\n\n\n<p>With the rise of complex therapies like biologics, cell and gene treatments, and targeted small molecules, early-stage trials have grown more intricate. For sponsors, getting this first step right means laying a solid foundation for everything that follows. This article dives into the critical elements of FIH trials, from interpreting preclinical data to trial design, site selection, regulatory strategy, risk management, and transition planning for Phase II.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">FIH trials: Objectives that matter<\/h2>\n\n\n\n<p><a href=\"https:\/\/credevo.com\/articles\/2021\/02\/05\/the-phase-of-study-clinical-trial-design\/\">First-in-human (FIH) trials <\/a>mark the first time a new drug is tested in people. At this stage, the focus isn\u2019t on whether the drug works, but whether it\u2019s safe\u2014and how the body responds to it. These early insights guide dosing, safety precautions, and future trial planning.<\/p>\n\n\n\n<p>First-in-human studies aim to answer a few essential questions:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Is the drug safe at low doses?<\/li>\n\n\n\n<li>What side effects appear, and how tolerable are they?<\/li>\n\n\n\n<li>How is the drug absorbed, distributed, metabolized, and excreted (ADME)?<\/li>\n\n\n\n<li>Does it interact with its intended target (pharmacodynamics)?<\/li>\n<\/ul>\n\n\n\n<p>Initial doses are kept deliberately low. Researchers closely monitor for even minor adverse effects\u2014shifts in lab values, changes in vital signs, or subjective discomfort. The primary goal is not efficacy but to define a safe exposure range.<\/p>\n\n\n\n<p>Understanding pharmacokinetics (PK) and pharmacodynamics (PD) is also crucial. Early PK data helps shape dose frequency (e.g., once-daily vs. long-acting), while PD signals can validate that the drug hits its target\u2014even if therapeutic outcomes remain distant.<\/p>\n\n\n\n<p>With these objectives in mind, the next step is to ensure the preclinical data supports a safe transition to human trials.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Preclinical foundations: Translating theory into human strategy<\/h3>\n\n\n\n<p>A sound FIH trial starts long before human dosing\u2014its groundwork is laid in preclinical studies. Animal and in vitro data provide key insights into the drug\u2019s pharmacology, toxicology, and potential mechanisms of harm.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Animal studies<\/strong> reveal how a drug behaves in a living system.<\/li>\n\n\n\n<li><strong>In vitro models<\/strong> help predict cellular interactions and possible off-target effects.<\/li>\n<\/ul>\n\n\n\n<p>These insights directly inform <strong>dose selection<\/strong>, <strong>route of administration<\/strong>, and <strong>early safety protocols<\/strong>. Preclinical toxicology, especially identifying a No Observed Adverse Effect Level (NOAEL), is vital for estimating a starting human dose.<\/p>\n\n\n\n<p>The next challenge is translating preclinical insights into a rational and safe starting dose for first-time human exposure.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Starting dose selection: MABEL, NOAEL, and safety factors<\/h4>\n\n\n\n<p>Choosing a starting dose is a high-stakes balancing act. Common strategies include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>MABEL (Minimum Anticipated Biological Effect Level):<\/strong> Used for novel agents where biological activity\u2014not toxicity\u2014is the first concern. It identifies the lowest dose expected to trigger any measurable effect.<\/li>\n\n\n\n<li><strong>NOAEL:<\/strong> Based on the highest dose in animals that caused no harm. It\u2019s often adjusted using <strong>allometric scaling<\/strong> to account for interspecies differences.<\/li>\n<\/ul>\n\n\n\n<p>Even with robust calculations, <strong>safety factors<\/strong> (typically 10-fold or more) are applied to buffer against uncertainty. Once a starting dose is chosen, trial design becomes the next priority.<\/p>\n\n\n\n<p>With a dose established, the next step is crafting a trial design that safely escalates exposure while collecting key data.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Trial design: SAD, MAD, and Adaptive models<\/strong><\/h3>\n\n\n\n<p>The structure of an FIH trial determines how risks are managed and data are collected. Three key designs dominate:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>SAD (Single Ascending Dose):<\/strong> Participants receive one dose, with close monitoring. If no safety concerns arise, the next cohort receives a higher dose. It\u2019s ideal for initial PK and tolerability assessments.<\/li>\n\n\n\n<li><strong>MAD (Multiple Ascending Dose):<\/strong> Builds on SAD by examining repeated dosing. It\u2019s essential for understanding drug accumulation, steady-state kinetics, and delayed adverse effects.<\/li>\n\n\n\n<li><strong>Adaptive Designs:<\/strong> Increasingly popular, adaptive trials allow modifications based on emerging data\u2014like dose adjustments or cohort expansions\u2014without compromising scientific integrity.<\/li>\n<\/ul>\n\n\n\n<blockquote class=\"wp-block-quote has-vivid-cyan-blue-background-color has-background is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"has-text-align-center has-white-color has-text-color has-link-color has-medium-font-size wp-elements-77f301b145fcddcf05ff2a0085c86a8a\">Want to learn more about adaptive trial designs? <a href=\"https:\/\/credevo.com\/articles\/2020\/09\/05\/clinical-trial-design-rct-adaptive-trial-designs-part-i\/\">click here<\/a><\/p>\n<\/blockquote>\n\n\n\n<p>Many FIH protocols now combine SAD and MAD components under one umbrella, streamlining development timelines.<\/p>\n\n\n\n<p>A robust design needs the right infrastructure and personnel, so choosing the right site and team is essential next.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Site and team selection: The human factor<\/h3>\n\n\n\n<p>The most elegant study design means little without the right site and personnel to carry it out.<\/p>\n\n\n\n<p>For FIH studies, choose a <strong>Phase I unit<\/strong> with:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>24\/7 medical oversight<\/li>\n\n\n\n<li>Emergency response readiness<\/li>\n\n\n\n<li>Experienced staff in early-phase protocols<\/li>\n\n\n\n<li>Robust PK sampling and lab capabilities<\/li>\n<\/ul>\n\n\n\n<p>Equally critical is the <strong>investigator team<\/strong>\u2014they must not only understand regulatory requirements but also have the judgment to handle unexpected adverse events and protocol deviations in real time.<\/p>\n\n\n\n<p>Once the trial setup is in place, sponsors must ensure ethical and regulatory compliance before dosing begins.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote has-white-color has-vivid-cyan-blue-background-color has-text-color has-background has-link-color has-medium-font-size wp-elements-313f7418fada7c966456bec0ffb981fc is-layout-flow wp-block-quote-is-layout-flow\">\n<p>Are you looking for expert support in planning your First-in-Human (FIH) clinical trial? Our experienced team can guide you through every step \u2014 from protocol development to regulatory strategy and site selection. Please fill out the form below to get in touch with us and start the conversation.<\/p>\n<\/blockquote>\n\n\n\n<h3 class=\"wp-block-heading\">Ethical and regulatory oversight: Protecting participants<\/h3>\n\n\n\n<p>In First-in-Human (FIH) trials, participant safety is protected through layered ethical and regulatory review \u2014 with an emphasis on anticipating the unknown.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Ethics Committees: Beyond just approval<\/h4>\n\n\n\n<p>Ethics Committees don\u2019t just greenlight protocols \u2014 they interrogate the <em>moral logic<\/em> behind exposing humans to a novel compound. They assess whether the <strong>preclinical package justifies human risk<\/strong>, and whether the <strong>starting dose<\/strong> is grounded in rigorous translational modeling (e.g., MABEL over NOAEL for biologics or high-risk compounds).<\/p>\n\n\n\n<p>They evaluate:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Trial design defensibility<\/strong>: Is there a clear escalation strategy? Are sentinel cohorts used appropriately?<\/li>\n\n\n\n<li><strong>Investigator readiness<\/strong>: Are staff trained to respond to first-dose reactions? Is ICU access guaranteed?<\/li>\n\n\n\n<li><strong>Risk communication<\/strong>: Does the consent form reflect real-world uncertainty, not just regulatory compliance?<\/li>\n\n\n\n<li><strong>Volunteer vulnerability<\/strong>: Is recruitment targeting socioeconomically disadvantaged groups through compensation?<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Ethical and regulatory oversight: Protecting participants<\/h3>\n\n\n\n<p>Ethics review also includes assessment of <strong>insurance coverage<\/strong>, <strong>post-trial care commitments<\/strong>, and <strong>biological sample use<\/strong>, which are often overlooked in early-phase trials.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Regulatory authorities: Scientific risk governance<\/strong><\/h4>\n\n\n\n<p>Agencies like the <a href=\"https:\/\/www.fda.gov\/\">FDA<\/a>, <a href=\"https:\/\/www.ema.europa.eu\/en\/homepage\">EMA<\/a>, or <a href=\"https:\/\/cdsco.gov.in\/opencms\/opencms\/en\/Home\/\">CDSCO<\/a> verify whether the science warrants first-in-human exposure. They examine:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Toxicology &amp; PK bridging data<\/strong><\/li>\n\n\n\n<li><strong>Manufacturing controls (CMC)<\/strong> under GMP<\/li>\n\n\n\n<li><strong>Dosing rationale<\/strong> with conservative safety margins<\/li>\n\n\n\n<li><strong>Real-time safety oversight<\/strong> (e.g., halting rules, telemetry, DMCs)<\/li>\n<\/ul>\n\n\n\n<p>Jurisdiction-specific variations matter \u2014 India mandates SAE compensation and EC registration, while the EU requires unified trial submission under the CTR system.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Global compliance: Harmonizing across borders<\/h4>\n\n\n\n<p>FIH trials often span multiple regions, demanding alignment with <a href=\"https:\/\/www.ema.europa.eu\/en\/ich-m3-r2-non-clinical-safety-studies-conduct-human-clinical-trials-pharmaceuticals-scientific-guideline\"><strong>ICH-GCP<\/strong>, <strong>ICH M3(R2)<\/strong><\/a>, and the <strong>Declaration of Helsinki<\/strong>. Yet ethical expectations vary \u2014 for instance, standards for informed consent or data privacy may diverge. Sponsors must synchronize ethics and regulatory submissions, ensure consistent safety oversight, and build flexibility for local nuances.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Risk management and safety monitoring<\/h3>\n\n\n\n<p>Participant safety is the cornerstone of FIH trials. Key mechanisms include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sentinel dosing:<\/strong> The first few participants receive the dose alone before the rest of the cohort. If any issues arise, escalation stops immediately.<\/li>\n\n\n\n<li><strong>Stopping rules:<\/strong> Predefined criteria halt the study or a dose level if adverse events surpass set thresholds.<\/li>\n\n\n\n<li><strong>Adverse Event Monitoring:<\/strong> Real-time tracking and rapid analysis of events allow for early intervention if patterns emerge.<\/li>\n\n\n\n<li><strong>Independent Safety Boards (DSMBs):<\/strong> Regular review of unblinded safety data ensures independent oversight and scientific accountability.<\/li>\n<\/ul>\n\n\n\n<p>Many sponsors choose to outsource operations, making CRO collaboration the next critical focus.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Not Just a CRO \u2014 A Partner Who Gets the Stakes<\/h3>\n\n\n\n<p>In First-in-Human (FIH) trials, outsourcing to a CRO is common \u2014 but the <em>type<\/em> of CRO you choose can quietly define your trial\u2019s trajectory. Are you hiring a task-taker, or aligning with a partner who thinks with you?<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Not Just \u201cCan They Do It?\u201d \u2014 But \u201cWill They Own It?<\/h4>\n\n\n\n<p>A CRO with the right certifications and SOPs can run a study. But a true partner helps you navigate uncertainty \u2014 from dose escalations and regulatory queries to unexpected safety flags. You want a CRO that:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Knows the regulatory nuance<\/strong> of early-phase work in your region(s)<\/li>\n\n\n\n<li>Has handled <strong>adaptive designs, MABEL-based dosing, or real-time risk monitoring<\/strong><\/li>\n\n\n\n<li>Can spot site-level red flags before you see them in the metrics<\/li>\n<\/ul>\n\n\n\n<h5 class=\"wp-block-heading\">Set the Relationship Up Right<\/h5>\n\n\n\n<p>Great outsourcing starts with clarity. Define:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ownership boundaries<\/strong>: Who leads protocol deviations? Who manages urgent SAEs?<\/li>\n\n\n\n<li><strong>Escalation pathways<\/strong>: What happens when a dose-halting rule is triggered on a weekend?<\/li>\n\n\n\n<li><strong>Shared visibility<\/strong>: Live dashboards and data access keep everyone aligned \u2014 without micromanagement<\/li>\n<\/ul>\n\n\n\n<h5 class=\"wp-block-heading\">Oversight Without Friction<\/h5>\n\n\n\n<p>You don\u2019t want to chase updates \u2014 but you <em>do<\/em> want oversight that lets you sleep at night. Best practices include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Joint risk reviews<\/strong> during screening and post-dose windows<\/li>\n\n\n\n<li><strong>Co-created KPIs<\/strong> that measure more than timelines \u2014 think data quality, protocol fidelity, and patient safety<\/li>\n\n\n\n<li><strong>Audit-ready documentation flows<\/strong> from day one<\/li>\n<\/ul>\n\n\n\n<p>Choosing the right CRO in FIH isn\u2019t about cost or capacity \u2014 it\u2019s about trust, reflexes, and shared risk. In high-uncertainty trials, your CRO shouldn\u2019t just follow your protocol. They should be ready to <em>think with you when the unexpected hits<\/em> \u2014 because it will.<\/p>\n\n\n\n<p>After trial completion, the final step is integrating results to inform and shape the next phase of development.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Preparing for Phase II: Turning insights into strategy<\/h3>\n\n\n\n<p>Once an FIH trial concludes, the focus shifts to leveraging data for the next phase.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Go\/No-Go Decisions:<\/strong> If safety, PK, and early PD signals align the program advances. If not, this is the point to reconsider or modify the asset.<\/li>\n\n\n\n<li><strong>Dose and Formulation Refinement:<\/strong> FIH results often reveal the need for formulation tweaks (e.g., shifting from capsule to tablet) or adjusting the dosing schedule based on bioavailability or patient feedback.<\/li>\n\n\n\n<li><strong>Informing Phase II Design:<\/strong> Early human data sharpen future protocols. This includes refining inclusion criteria, safety monitoring plans, and selecting endpoints that are more likely to show meaningful clinical signals.<\/li>\n<\/ul>\n\n\n\n<p>All of these components reinforce why a well-executed FIH trial is essential to long-term development success.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Conclusion: FIH as the bedrock of clinical development<\/h3>\n\n\n\n<p>First-in-human trials are more than a procedural checkpoint\u2014they\u2019re the <strong>bedrock of modern clinical development<\/strong>. These trials translate theoretical promise into practical reality, guiding whether a compound should proceed or pivot. When executed with precision, FIH studies provide the clarity sponsors need to move confidently into Phase II and beyond.<\/p>\n\n\n\n<p>The future of medicine depends on safe, smart, and ethically grounded early-phase research. Sponsors who get this step right don\u2019t just reduce risk\u2014they gain critical strategic insight that informs every subsequent decision on the path to approval.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Have questions about how to kickstart your First-in-Human (FIH) clinical trial?<\/h2>\n\n\n\n<p>Whether you&#8217;re planning your first FIH study or refining your strategy, our experts are here to support you every step of the way. Share your requirements using the form below, and we\u2019ll help you get started with confidence.<\/p>\n\n\n<div class=\"wpforms-container wpforms-container-full\" id=\"wpforms-10550\"><form id=\"wpforms-form-10550\" class=\"wpforms-validate wpforms-form\" data-formid=\"10550\" method=\"post\" enctype=\"multipart\/form-data\" action=\"\/articles\/wp-json\/wp\/v2\/posts\/10543\" data-token=\"796244c9cc4ba131c41bd8209f62d59a\" data-token-time=\"1776792165\"><noscript class=\"wpforms-error-noscript\">Please enable JavaScript in your browser to complete this form.<\/noscript><div class=\"wpforms-field-container\"><div id=\"wpforms-10550-field_9-container\" class=\"wpforms-field wpforms-field-textarea\" data-field-id=\"9\"><label class=\"wpforms-field-label\" for=\"wpforms-10550-field_9\">Provide your requirement details here <span class=\"wpforms-required-label\">*<\/span><\/label><textarea id=\"wpforms-10550-field_9\" class=\"wpforms-field-medium wpforms-field-required\" name=\"wpforms[fields][9]\" required><\/textarea><\/div><div id=\"wpforms-10550-field_1-container\" class=\"wpforms-field wpforms-field-email\" data-field-id=\"1\"><label class=\"wpforms-field-label\" for=\"wpforms-10550-field_1\">What is your work email? <span class=\"wpforms-required-label\">*<\/span><\/label><input type=\"email\" id=\"wpforms-10550-field_1\" class=\"wpforms-field-medium wpforms-field-required\" name=\"wpforms[fields][1]\" spellcheck=\"false\" required><div class=\"wpforms-field-description\">Provide your work email, where we can contact you.<\/div><\/div><\/div><!-- .wpforms-field-container --><div class=\"wpforms-field wpforms-field-hp\"><label for=\"wpforms-10550-field-hp\" class=\"wpforms-field-label\">Email<\/label><input type=\"text\" name=\"wpforms[hp]\" id=\"wpforms-10550-field-hp\" class=\"wpforms-field-medium\"><\/div><div class=\"wpforms-recaptcha-container wpforms-is-recaptcha wpforms-is-recaptcha-type-v2\" ><div class=\"g-recaptcha\" data-sitekey=\"6LeaQRYTAAAAAPo7U8jnZJBUndxcS3f0E3Vijb2k\"><\/div><input type=\"text\" name=\"g-recaptcha-hidden\" class=\"wpforms-recaptcha-hidden\" style=\"position:absolute!important;clip:rect(0,0,0,0)!important;height:1px!important;width:1px!important;border:0!important;overflow:hidden!important;padding:0!important;margin:0!important;\" data-rule-recaptcha=\"1\"><\/div><div class=\"wpforms-submit-container\" ><input type=\"hidden\" name=\"wpforms[id]\" value=\"10550\"><input type=\"hidden\" name=\"page_title\" value=\"\"><input type=\"hidden\" name=\"page_url\" value=\"https:\/\/credevo.com\/articles\/wp-json\/wp\/v2\/posts\/10543\"><input type=\"hidden\" name=\"url_referer\" value=\"\"><button type=\"submit\" name=\"wpforms[submit]\" id=\"wpforms-submit-10550\" class=\"wpforms-submit\" data-alt-text=\"Sending...\" data-submit-text=\"Submit\" aria-live=\"assertive\" value=\"wpforms-submit\">Submit<\/button><\/div><\/form><\/div>  <!-- .wpforms-container -->\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n","protected":false},"excerpt":{"rendered":"<p>Stepping into a first-in-human (FIH) clinical trial is a defining moment in drug development. It\u2019s when a new drug that\u2019s been years in the making finally transitions from lab bench to bedside. This isn\u2019t about proving efficacy\u2014that comes later. FIH clinical trials are all about safety, tolerability, and understanding how the drug behaves in the [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":10544,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"cybocfi_hide_featured_image":"yes","footnotes":""},"categories":[2,13,12,14],"tags":[45,152,687],"class_list":["post-10543","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical-research","category-clinical-site","category-clinical-trial","category-clinical-trial-feasibility","tag-clinicaltrials","tag-fih","tag-startegy"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>First-in-Human Trials: Key Considerations for Sponsors.<\/title>\n<meta name=\"description\" content=\"Explore key safety and design considerations for sponsors planning first-in-human (FIH) clinical trials. Learn more.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/credevo.com\/articles\/2025\/01\/05\/first-in-human-fih-clinical-trials-key-considerations-for-sponsors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"First-in-Human Trials: Key Considerations for Sponsors.\" \/>\n<meta property=\"og:description\" content=\"Explore key safety and design considerations for sponsors planning first-in-human (FIH) clinical trials. Learn more.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/credevo.com\/articles\/2025\/01\/05\/first-in-human-fih-clinical-trials-key-considerations-for-sponsors\/\" \/>\n<meta property=\"og:site_name\" content=\"Credevo Articles\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/credevo\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-05T04:30:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-21T10:46:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/credevo.com\/articles\/wp-content\/uploads\/2025\/05\/First_In_Human_Clinical_Trials_Sponsors_Credevo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"450\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trial Expert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@gocredevo\" \/>\n<meta name=\"twitter:site\" content=\"@gocredevo\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trial Expert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/credevo.com\/articles\/2025\/01\/05\/first-in-human-fih-clinical-trials-key-considerations-for-sponsors\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/credevo.com\/articles\/2025\/01\/05\/first-in-human-fih-clinical-trials-key-considerations-for-sponsors\/\"},\"author\":{\"name\":\"Trial Expert\",\"@id\":\"https:\/\/credevo.com\/articles\/#\/schema\/person\/27532d20071183286988a29ea878a2ec\"},\"headline\":\"First-in-Human (FIH) Clinical Trials: Key Considerations for Sponsors\",\"datePublished\":\"2025-01-05T04:30:00+00:00\",\"dateModified\":\"2025-07-21T10:46:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/credevo.com\/articles\/2025\/01\/05\/first-in-human-fih-clinical-trials-key-considerations-for-sponsors\/\"},\"wordCount\":1809,\"publisher\":{\"@id\":\"https:\/\/credevo.com\/articles\/#organization\"},\"image\":{\"@id\":\"https:\/\/credevo.com\/articles\/2025\/01\/05\/first-in-human-fih-clinical-trials-key-considerations-for-sponsors\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/credevo.com\/articles\/wp-content\/uploads\/2025\/05\/First_In_Human_Clinical_Trials_Sponsors_Credevo.jpg\",\"keywords\":[\"clinicaltrials\",\"fih\",\"Startegy\"],\"articleSection\":[\"Clinical Research\",\"clinical site\",\"clinical trial\",\"clinical trial feasibility\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/credevo.com\/articles\/2025\/01\/05\/first-in-human-fih-clinical-trials-key-considerations-for-sponsors\/\",\"url\":\"https:\/\/credevo.com\/articles\/2025\/01\/05\/first-in-human-fih-clinical-trials-key-considerations-for-sponsors\/\",\"name\":\"First-in-Human Trials: Key Considerations for Sponsors.\",\"isPartOf\":{\"@id\":\"https:\/\/credevo.com\/articles\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/credevo.com\/articles\/2025\/01\/05\/first-in-human-fih-clinical-trials-key-considerations-for-sponsors\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/credevo.com\/articles\/2025\/01\/05\/first-in-human-fih-clinical-trials-key-considerations-for-sponsors\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/credevo.com\/articles\/wp-content\/uploads\/2025\/05\/First_In_Human_Clinical_Trials_Sponsors_Credevo.jpg\",\"datePublished\":\"2025-01-05T04:30:00+00:00\",\"dateModified\":\"2025-07-21T10:46:27+00:00\",\"description\":\"Explore key safety and design considerations for sponsors planning first-in-human (FIH) clinical trials. Learn more.\",\"breadcrumb\":{\"@id\":\"https:\/\/credevo.com\/articles\/2025\/01\/05\/first-in-human-fih-clinical-trials-key-considerations-for-sponsors\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/credevo.com\/articles\/2025\/01\/05\/first-in-human-fih-clinical-trials-key-considerations-for-sponsors\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/credevo.com\/articles\/2025\/01\/05\/first-in-human-fih-clinical-trials-key-considerations-for-sponsors\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/credevo.com\/articles\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"First-in-Human (FIH) Clinical Trials: Key Considerations for Sponsors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/credevo.com\/articles\/#website\",\"url\":\"https:\/\/credevo.com\/articles\/\",\"name\":\"Credevo\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/credevo.com\/articles\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/credevo.com\/articles\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/credevo.com\/articles\/#organization\",\"name\":\"Credevo Pte. Ltd.\",\"url\":\"https:\/\/credevo.com\/articles\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/credevo.com\/articles\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/credevo.com\/articles\/wp-content\/uploads\/2021\/04\/CREDEVO-HORIZONTAL.jpg\",\"contentUrl\":\"https:\/\/credevo.com\/articles\/wp-content\/uploads\/2021\/04\/CREDEVO-HORIZONTAL.jpg\",\"width\":320,\"height\":119,\"caption\":\"Credevo Pte. Ltd.\"},\"image\":{\"@id\":\"https:\/\/credevo.com\/articles\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/credevo\",\"https:\/\/x.com\/gocredevo\",\"https:\/\/www.instagram.com\/credevo_official\/\",\"https:\/\/www.linkedin.com\/company\/credevo\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/credevo.com\/articles\/#\/schema\/person\/27532d20071183286988a29ea878a2ec\",\"name\":\"Trial Expert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/credevo.com\/articles\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/07b120d666645220d4fd5b49e154d849?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/07b120d666645220d4fd5b49e154d849?s=96&d=mm&r=g\",\"caption\":\"Trial Expert\"},\"url\":\"https:\/\/credevo.com\/articles\/author\/trialexpert\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"First-in-Human Trials: Key Considerations for Sponsors.","description":"Explore key safety and design considerations for sponsors planning first-in-human (FIH) clinical trials. Learn more.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/credevo.com\/articles\/2025\/01\/05\/first-in-human-fih-clinical-trials-key-considerations-for-sponsors\/","og_locale":"en_US","og_type":"article","og_title":"First-in-Human Trials: Key Considerations for Sponsors.","og_description":"Explore key safety and design considerations for sponsors planning first-in-human (FIH) clinical trials. Learn more.","og_url":"https:\/\/credevo.com\/articles\/2025\/01\/05\/first-in-human-fih-clinical-trials-key-considerations-for-sponsors\/","og_site_name":"Credevo Articles","article_publisher":"https:\/\/www.facebook.com\/credevo","article_published_time":"2025-01-05T04:30:00+00:00","article_modified_time":"2025-07-21T10:46:27+00:00","og_image":[{"width":800,"height":450,"url":"https:\/\/credevo.com\/articles\/wp-content\/uploads\/2025\/05\/First_In_Human_Clinical_Trials_Sponsors_Credevo.jpg","type":"image\/jpeg"}],"author":"Trial Expert","twitter_card":"summary_large_image","twitter_creator":"@gocredevo","twitter_site":"@gocredevo","twitter_misc":{"Written by":"Trial Expert","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/credevo.com\/articles\/2025\/01\/05\/first-in-human-fih-clinical-trials-key-considerations-for-sponsors\/#article","isPartOf":{"@id":"https:\/\/credevo.com\/articles\/2025\/01\/05\/first-in-human-fih-clinical-trials-key-considerations-for-sponsors\/"},"author":{"name":"Trial Expert","@id":"https:\/\/credevo.com\/articles\/#\/schema\/person\/27532d20071183286988a29ea878a2ec"},"headline":"First-in-Human (FIH) Clinical Trials: Key Considerations for Sponsors","datePublished":"2025-01-05T04:30:00+00:00","dateModified":"2025-07-21T10:46:27+00:00","mainEntityOfPage":{"@id":"https:\/\/credevo.com\/articles\/2025\/01\/05\/first-in-human-fih-clinical-trials-key-considerations-for-sponsors\/"},"wordCount":1809,"publisher":{"@id":"https:\/\/credevo.com\/articles\/#organization"},"image":{"@id":"https:\/\/credevo.com\/articles\/2025\/01\/05\/first-in-human-fih-clinical-trials-key-considerations-for-sponsors\/#primaryimage"},"thumbnailUrl":"https:\/\/credevo.com\/articles\/wp-content\/uploads\/2025\/05\/First_In_Human_Clinical_Trials_Sponsors_Credevo.jpg","keywords":["clinicaltrials","fih","Startegy"],"articleSection":["Clinical Research","clinical site","clinical trial","clinical trial feasibility"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/credevo.com\/articles\/2025\/01\/05\/first-in-human-fih-clinical-trials-key-considerations-for-sponsors\/","url":"https:\/\/credevo.com\/articles\/2025\/01\/05\/first-in-human-fih-clinical-trials-key-considerations-for-sponsors\/","name":"First-in-Human Trials: Key Considerations for Sponsors.","isPartOf":{"@id":"https:\/\/credevo.com\/articles\/#website"},"primaryImageOfPage":{"@id":"https:\/\/credevo.com\/articles\/2025\/01\/05\/first-in-human-fih-clinical-trials-key-considerations-for-sponsors\/#primaryimage"},"image":{"@id":"https:\/\/credevo.com\/articles\/2025\/01\/05\/first-in-human-fih-clinical-trials-key-considerations-for-sponsors\/#primaryimage"},"thumbnailUrl":"https:\/\/credevo.com\/articles\/wp-content\/uploads\/2025\/05\/First_In_Human_Clinical_Trials_Sponsors_Credevo.jpg","datePublished":"2025-01-05T04:30:00+00:00","dateModified":"2025-07-21T10:46:27+00:00","description":"Explore key safety and design considerations for sponsors planning first-in-human (FIH) clinical trials. Learn more.","breadcrumb":{"@id":"https:\/\/credevo.com\/articles\/2025\/01\/05\/first-in-human-fih-clinical-trials-key-considerations-for-sponsors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/credevo.com\/articles\/2025\/01\/05\/first-in-human-fih-clinical-trials-key-considerations-for-sponsors\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/credevo.com\/articles\/2025\/01\/05\/first-in-human-fih-clinical-trials-key-considerations-for-sponsors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/credevo.com\/articles\/"},{"@type":"ListItem","position":2,"name":"First-in-Human (FIH) Clinical Trials: Key Considerations for Sponsors"}]},{"@type":"WebSite","@id":"https:\/\/credevo.com\/articles\/#website","url":"https:\/\/credevo.com\/articles\/","name":"Credevo","description":"","publisher":{"@id":"https:\/\/credevo.com\/articles\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/credevo.com\/articles\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/credevo.com\/articles\/#organization","name":"Credevo Pte. Ltd.","url":"https:\/\/credevo.com\/articles\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/credevo.com\/articles\/#\/schema\/logo\/image\/","url":"https:\/\/credevo.com\/articles\/wp-content\/uploads\/2021\/04\/CREDEVO-HORIZONTAL.jpg","contentUrl":"https:\/\/credevo.com\/articles\/wp-content\/uploads\/2021\/04\/CREDEVO-HORIZONTAL.jpg","width":320,"height":119,"caption":"Credevo Pte. Ltd."},"image":{"@id":"https:\/\/credevo.com\/articles\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/credevo","https:\/\/x.com\/gocredevo","https:\/\/www.instagram.com\/credevo_official\/","https:\/\/www.linkedin.com\/company\/credevo"]},{"@type":"Person","@id":"https:\/\/credevo.com\/articles\/#\/schema\/person\/27532d20071183286988a29ea878a2ec","name":"Trial Expert","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/credevo.com\/articles\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/07b120d666645220d4fd5b49e154d849?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/07b120d666645220d4fd5b49e154d849?s=96&d=mm&r=g","caption":"Trial Expert"},"url":"https:\/\/credevo.com\/articles\/author\/trialexpert\/"}]}},"_links":{"self":[{"href":"https:\/\/credevo.com\/articles\/wp-json\/wp\/v2\/posts\/10543"}],"collection":[{"href":"https:\/\/credevo.com\/articles\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/credevo.com\/articles\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/credevo.com\/articles\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/credevo.com\/articles\/wp-json\/wp\/v2\/comments?post=10543"}],"version-history":[{"count":11,"href":"https:\/\/credevo.com\/articles\/wp-json\/wp\/v2\/posts\/10543\/revisions"}],"predecessor-version":[{"id":10569,"href":"https:\/\/credevo.com\/articles\/wp-json\/wp\/v2\/posts\/10543\/revisions\/10569"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/credevo.com\/articles\/wp-json\/wp\/v2\/media\/10544"}],"wp:attachment":[{"href":"https:\/\/credevo.com\/articles\/wp-json\/wp\/v2\/media?parent=10543"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/credevo.com\/articles\/wp-json\/wp\/v2\/categories?post=10543"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/credevo.com\/articles\/wp-json\/wp\/v2\/tags?post=10543"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}